MGNX News and Press, MacroGenics Inc. From 03/22/23

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration&#...

2023-03-20 18:59:53 ET The stock of cancer-focused biotech MacroGenics (NASDAQ: MGNX) was off to a good start this week. It received a nice price bump on the back of two price-target hikes by pundits following the stock. The shares closed the day higher by 0.6%, which nearly met the...

2023-03-16 17:24:42 ET Gainers: Hub Cyber Security ( HUBC ) +6% . Altimmune ( ALT ) +5% . Hawaiian Holdings ( HA ) +4% . MacroGenics ( MGNX ) +3% . PENN Entertainment ( PENN ) +3% . Losers: Sarepta Therapeutics ( NASDAQ...

2023-03-16 12:17:29 ET Shares of MacroGenics (NASDAQ: MGNX) were up 14.5% in early trading Thursday thanks to a strong 2022 earnings report that it released after the market closed Wednesday. The biotech company focuses on monoclonal antibody-based therapeutics to treat cancer. ...

2023-03-16 11:50:35 ET MacroGenics ( NASDAQ: MGNX ) stock rose ~13% on Thursday after FY22 revenue beat estimates. Net loss narrowed to -$119.76M, compared to -$202.12M in Full year 2021. Total revenues grew +96.2% Y/Y to $151.94M, surpassing analysts estimates. ...

2023-03-15 23:00:35 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q4 2022 Earnings Call Mar 15, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q4 2022 Earnings Call Transcript

2023-03-15 19:33:05 ET MacroGenics, Inc. (MGNX) Q4 2022 Earnings Conference Call March 15, 2023 4:30 P.M. ET Company Participants Jim Karrels - Senior Vice President and Chief Financial Officer Scott Koenig - President and Chief Executive Officer Conference Cal...

2023-03-15 16:05:21 ET MacroGenics press release ( NASDAQ: MGNX ): FY GAAP EPS of -$1.95 misses by $0.07 . Revenue of $151.94M (+96.2% Y/Y) beats by $1.88M . Cash, cash equivalents and marketable securities as of December 31, 2022, were $154.3 million, com...

Cash runway extended through 2025 with $ 250 million in non-dilutive funding over past eight months TAMARACK study design modified with objective of accelerating data readout Encouraging lorigerlimab (PD-1 × CTLA-4 bispecific DART ® molecule) monotherapy...

2023-03-14 08:34:09 ET Synaffix has announced the expansion of its license agreement with MacroGenics ( NASDAQ: MGNX ), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The ...